CYCN · As filed with the SEC
Korsana Biosciences income statement, by quarter
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Total revenues | — | 0 | — | 875,000 |
| Revenue from purchase agreement | — | — | — | 800,000 |
| Revenue from option agreement | — | 0 | — | 75,000 |
| Cost and expenses: | ||||
| Research and development | — | 730,000 | — | 348,000 |
| General and administrative | 1,771,000 | 2,479,000 | — | 1,533,000 |
| Total cost and expenses | 1,771,000 | 3,209,000 | — | 1,881,000 |
| Loss from operations | (1,771,000) | (3,209,000) | — | (1,006,000) |
| Other income, net | ||||
| Interest income | 16,000 | 32,000 | — | 30,000 |
| Gain from settlement of account payable | — | — | — | 0 |
| Gain from insurance recovery | — | — | — | 0 |
| Net loss | — | — | — | (976,000) |
| Total other income, net | 16,000 | 32,000 | — | 30,000 |
| Net loss and other comprehensive loss | (1,755,000) | (3,177,000) | — | — |
| Net loss per share: | ||||
| Basic net loss per share | (0.41) | (0.76) | — | (0.3) |
| Diluted net loss per share | (0.41) | (0.76) | — | (0.3) |
| Weighted average shares used in calculating: | ||||
| Basic shares | 4,251,000 | 4,205,000 | — | 3,225,000 |
| Diluted shares | 4,251,000 | 4,205,000 | — | 3,225,000 |
| Net loss | — | — | — | (976,000) |
| Foreign currency translation adjustment loss | — | — | — | 0 |
| Comprehensive loss | — | — | — | (976,000) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.